The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction

Sodium-glucose cotransporter type 2 (SGLT2) inhibitors are a relatively new class of antihyperglycemic drug with salutary effects on glucose control, body weight, and blood pressure. Emerging evidence now indicates that these drugs may have a beneficial effect on outcomes in heart failure with reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Genuardi, Michael V., Mather, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010852/
https://www.ncbi.nlm.nih.gov/pubmed/33779401
http://dx.doi.org/10.1177/17539447211002678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010852/
https://www.ncbi.nlm.nih.gov/pubmed/33779401
http://dx.doi.org/10.1177/17539447211002678

Ejemplares similares